ShajiKKumarMD

Hematology • Rochester, MN

Hematologic Oncology

Consultant at Mayo Clinic

Join to view full profile

Dr. Kumar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kumar's full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1999 - 2003
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1997 - 1999
Institute Rotary Cancer Hospital, All-India Institute of Medical SciencesSenior Resident, 1996 - 1997
All India Institute of Medical SciencesClass of 1993
All-India Institute of Medical SciencesInternship, 1992
All-India Institute of Medical SciencesMB BS, 1987 - 1991
Union Christian CollegePre-Medical, 1985 - 1987

Certifications & Licensure

MN State Medical License 1999 - 2025
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Merit Award American Society of Clinical Oncology, 2003
William Summerskill Award Department of Internal Medicine, Mayo, 2003
Travel Award for Presentation at Special Topic Conference on Hepatic Veno-occlusive Disease, Atlanta, GA American Association for the Study of Liver Diseases, 2002
Methods in Clinical Cancer Research Award American Association for Cancer Research amd American Society of Clinical Oncology Workshop, 2002
Cancer Education Consortium Award Epidemiology and Trial Design, Brewster, MA, 2002
American Association of Cancer Research Award Molecular Biology Workshop, Aspen, CO, 2001
Kirpal Kaur Award for Best Resident Department of Medicine, All India Institute of Medical Sciences, New Delhi, 1993
Join now to see all

Clinical Trials

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer Start of enrollment: 2005 Dec 01
Completed
Phase 1
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma Start of enrollment: 2007 Aug 29
Completed
Phase 1, Phase 2
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2006 Jul 01
Completed
Phase 2
Sunitinib in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2007 Sep 01
Completed
Phase 2
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Start of enrollment: 2007 Dec 01
Completed
Phase 2
Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2008 May 01
Terminated
Phase 2
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2008 Aug 01
Terminated
Phase 1
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Dec 03
Completed
Phase 2
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Start of enrollment: 2009 Jun 01
Completed
Phase 1, Phase 2
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant Start of enrollment: 2009 Dec 01
Completed
Phase 2
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2010 Feb 01
Completed
Phase 1, Phase 2
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2010 Feb 01
Completed
Phase 1, Phase 2
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis Start of enrollment: 2010 Mar 01
Completed
Phase 2
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib Start of enrollment: 2012 Jan 31
ACTIVE_NOT_RECRUITING
PHASE2
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2012 Dec 19
Completed
Phase 1
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide Start of enrollment: 2014 Mar 01
Completed
Phase 2
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant Start of enrollment: 2013 Aug 01
Withdrawn
Phase 2
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis Start of enrollment: 2013 Aug 20
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2013 Aug 01
Completed
Phase 1
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2014 Jun 30
Completed
Phase 1, Phase 2
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant Start of enrollment: 2018 May 25
Active, not recruiting
Phase 2
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma Start of enrollment: 2018 May 02
COMPLETED
PHASE1
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2020 Aug 07
Withdrawn
Phase 2
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) Start of enrollment: 2019 Sep 25
Active, not recruiting
Phase 1, Phase 2
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial Start of enrollment: 2022 Feb 16
COMPLETED
PHASE3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial Start of enrollment: 2021 Feb 24
RECRUITING
PHASE3
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma Start of enrollment: 2021 Jun 03
Completed
Phase 1, Phase 2
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) Start of enrollment: 2021 Apr 20
TERMINATED
PHASE1, PHASE2
Roles: Principal Investigator
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2020 Feb 05
Terminated
Phase 1
Roles: Principal Investigator
Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
COMPLETED
PHASE1, PHASE2
Roles: Contact
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis Start of enrollment: 2024 Feb 15
RECRUITING
PHASE1, PHASE2
Roles: Contact, Principal Investigator
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
COMPLETED
PHASE1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials.
Sarah N Price, Ju-Whei Lee, Ilana F Gareen, Sheetal M Kircher, Shaji K Kumar
Journal of Pain and Symptom Management. 2025-04-01
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.
Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer
Blood Advances. 2025-03-15
Cumulative deficits frailty index and relationship status predict survival in multiple myeloma.
Nadine Abdallah, Paul Dizona, Amanika Kumar, Betsy LaPlant, Terri Menser
Blood Advances. 2025-03-11

Journal Articles

Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple Myeloma
S Vincent Rajkumar, Yi L Hwa, Wilson I Gonsalves, Francis K Buadi, Angela Dispenzieri, Prashant Kapoor, Miriam A Hobbs, Martha Q Lacy, John A Lust, Robert A Kyle, Mori..., Nature
Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell Transplantation
Nelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of Relapse
Angela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature
Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia
Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
Daratumumab-Based Therapy in Patients with Heavily-Pretreated AL Amyloidosis
Saurabh Zanwar, Angela Dispenzieri, Wilson Gonsalves, David Dingli, Jithma P Abeykoon, Martha Q Lacy, Shaji Kumar, Nelson Leung, Morie A Gertz, Eli Muchtar, Francis Bu..., Nature
Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy: Failure of the Serum Free Light Chain Ratio
Morie A Gertz, David Dingli, Miriam Hobbs, John A Lust, Ronald S Go, Amie Fonder, Yi Lin, Shaji K Kumar, Prashant Kapoor, Taxiarchis V Kourelis, S Vincent Rajkumar, Ro..., Nature
Risk of MGUS in Relatives of Multiple Myeloma Cases by Clinical and Tumor Characteristics
Robert A Kyle, S Vincent Rajkumar, Alexandra J Greenberg, Abdul Rishi, Shaji Kumar, Nature
Comparable Outcomes Using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
Morie A Gertz, Shaji K Kumar, Martha Q Lacy, Prashant Kapoor, Suzanne R Hayman, Robert C Wolf, William J Hogan, Wilson I Gonsalves, Angela A Dispenzieri, David Dingli,..., Nature
Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...
John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
Renal failure with skeletal abnormalities.
Guleria R, Kumar S, Agarwal S, Prasad L, Postgrad Med J
Hypercalcemia complicating leukemic transformation of agnogenic myeloid metaplasia-myelofibrosis.
Kumar S, Mow BM, Kaufmann SH, Mayo Clin Proc
On appetite and its loss.
Jatoi A, Kumar S, Sloan JA, Nguyen PL, J Clin Oncol
Adjuvant chemotherapy for colon cancer.
Kumar SK, Goldberg RM, Curr Oncol Rep
59-year-old man with pelvic pain and hypergammaglobulinemia.
Kumar S, Lacy MQ, Mayo Clin Proc
Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Harmsen WS, Litzow MR, Bone Marrow Transplant
Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation.
Capizzi SA, Kumar S, Huneke NE, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Gastineau DA, Prakash UB, Tefferi A, Bone Marrow Transplant
Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of ...
Kumar S, Tefferi A, Ann Hematol
High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis.
Kumar S, Dispenzieri A, Lacy MQ, Litzow MR, Gertz MA, Bone Marrow Transplant
Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leuk...
Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR, Bone Marrow Transplant
Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
Tefferi A, Kumar S, Wolf RC, Lacy MQ, Inwards DJ, Gloor JM, Albright RC, Kamath PS, Litzow MR, Bone Marrow Transplant
Mesenteric venous thrombosis.
Kumar S, Sarr MG, Kamath PS, N Engl J Med
Acquired von Willebrand disease.
Kumar S, Pruthi RK, Nichols WL, Mayo Clin Proc
Agnogenic myeloid metaplasia associated with Klinefelter syndrome: a case report.
Kumar S, Menke DM, Dewald GW, Colon-Otero G, Ann Hematol
Thalidomide as an anti-cancer agent.
Kumar S, Witzig TE, Rajkumar SV, Journal of Cellular & Molecular Medicine. 2002 Apr-Jun
Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses.
Kumar S, Diehn FE, Gertz MA, Tefferi A, Ann Hematol
Join now to see all

Books/Book Chapters

Clinical malignant hematology.
Chapter: Monoclonal gammopathy of undetermined significance
Page 943 - 954Kumar S, Greipp PREditors: Sekeres MA, Kalaycio ME, Bolwell BJ.McGraw-Hill Medical, New York
Myeloma therapy: pursuing the plasma cell.
Chapter: Lenalidomide for initial therapy of newly diagnosed multiple myeloma
Page 279 - 288Kumar SEditors: Lonial S.Humana, Totowa
Antiangiogenic cancer therapy.
Chapter: Pathophysiologic role of VEGF in hematologic malignancies
Page 91 - 129Podar K, Kumar S, Chauhan D, Anderson KCEditors: Davis DW, Herbst RS, Abbruzzese JL.CRC Press, Boca Raton
Protein misfolding diseases: current and emerging principles and therapies.
Chapter: Current therapies for light-chain amyloidosis
Dispenzieri A, Kumar SEditors: Ramirez-Alvarado M; Kelly JW; Dobson CM.Wiley, Hoboken
Multiple Myeloma Kumar S. Vol. 1.
Kumar SDemos Medical, New York
Join now to see all

Abstracts/Posters

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venet...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple My...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in ...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venet...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagno...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Tra...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible f...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Association between a Polygenic Risk Score for Multiple Myeloma Risk and Overall Survival
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Immunological Consequences of Lenalidomide with and without Dexamethasone in Newly Diagnosed Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Approaches To Achieve the Best Possible Outcomes in Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.
2019 ASCO Annual Meeting - 6/1/2019
Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Lysine-Specific Demethylase KDM4A/JMJD2A Acts As a Tumor Suppressor in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical TrialsClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long-Term Survivorship with Active Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
New Strategies for Multiple Myeloma Care: Next Steps for The Future
60th American Society of Hematology Annual Meeting - 11/30/2018
ENMD-0995 (S 3-APG), a Novel Thalidomide Analogue, Has Promising Clinical Activity for Patients with Relapsed Refractory Multiple Myeloma. Preliminary Results of a Pha...
American Society of Hematology Annual Meeting San Diego, California
Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance.
American Society of Hematology Annual Meeting San Diego, California
Novel Therapies for Multiple Myeloma.
American Society of Hematology Annual Meeting Atlanta, Georgia
Stem Cell Transplantation for Myeloma.
Invited lecture for fellows Buffalo, New York
Can novel agents replace autologous stem cell transplantation (HDT) in myeloma?
Cascais, Portugal
Prognostic Factors and Staging system in Multiple Myeloma.
San Juan, Puerto Rico
Therapeutic Interventions to Prevent Progression of MGUS to Multiple Myeloma.
AACR Cancer Prevention Meeting 2008 Washington, District of Columbia
Improving Outcomes in Multiple Myeloma: Optimizing Induction Therapy in the Transplant Setting.
Massachusetts General Hospital Boston, Massachusetts
Anti-angiogenic therapies for Multiple Myeloma.
International Myeloma Workshop 2009 Washington, District of Columbia
Stem cell transplantation in the era of _novel agents: keeping options open.
EBMT Annual Meeting Education Program Gothenburg, Sweden
Multiple Myeloma: A “Decade of Progress”.
Medical Grand Rounds at RUSH Chicago, Illinois
Join now to see all

Press Mentions

$Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates from the Annual Hematology Meeting$
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates from the Annual Hematology MeetingFebruary 10th, 2025
Will You Be Attending This Session at ASH?December 3rd, 2024
Triplet and Quadruplet Regimens in Smoldering Multiple MyelomaFebruary 22nd, 2023
Join now to see all

Grant Support

Impact of Genetic susceptibility along the continuum from MGUS to MMMAYO CLINIC ROCHESTER2022–2027
Onset and biomarkers for progression of monoclonal gammopathiesMAYO CLINIC ROCHESTER2012–2025